Oncology / Cancer

 

16 Results were found on Technologies

10-2008-86

Targeting Bone Neoplasms and Other Cancers with Novel Combined Anticancer and Anti-Angiogenic Polymer Therapeutics

Anti-cancer NanoTherapyUtilizing unique nano-technology to develop targeted combination nanomedicines that were shown to be synergistic, effective and safe for treating cancer TechnologyWe have developed a new platform technology for the treatment of cancer and bone metastases using combined targeted nano-sized polymers that deliver chemotherapeutics creating a new class of effective and safer molecules. The novel […] Read More >

Leading Researchers:
5-2012-401

Biomarkers for Risk Assessment in Colorectal Cancer Patients

Mortalin (also known as GRP75 and mitochondrial stress protein 70) is a ubiquitously expressed mitochondrial chaperone related to the cytosolic heat shock protein 70 (HSP70). It protects cells from senescence and apoptosis and is overexpressed in most cancer cells. We discovered that cell resistance to complement-dependent cytotoxicity depends on mortalin and that mortalin is released […] Read More >

Leading Researchers:
10-2013-551

Novel Integrase Based Cancer Treatment Technology

We have developed a new gene therapy technology for specific cancer cells killing and validated both efficacy and safety superiority of the proposed system over the conventional one in lung cancer mice model. The proposed system offers advantages over already known counterparts and may therefore be developed into a safer and efficient human cancer treatment […] Read More >

Leading Researchers:
10-2018-1153

An Oncolytic Virus That Exploits Immune Defects of Cancer Cells

An oncolytic virus for tumors of different etiology presenting defects in interferon signaling, designed as a potent, specific and safe therapy.  Promising in-vivo murine melanoma model shows potential for development as a mono or an add-on to chemotherapy or check-point inhibitors. UNMET NEEDOn Nov. 2015 the FDA approved the first oncolytic virus based treatment. Oncolytic […] Read More >

Leading Researchers:
2-2016-991

A Novel Nanoparticle that Selectively Delivers RNAi Oligonucelotides to Tumors, Preventing Side Effects to Tissues

UNMET NEEDPancreatic cancer numbers among the most aggressive cancers known today. The overwhelming majority of pancreatic cancer patients pass away within just a year of diagnosis. However, a small minority of patients may live several years with the disease. Our findings pinpoint the inverse correlation between a known oncogene (PLK1) and the expression of an […] Read More >

Leading Researchers:
2-2019-1243

Therapeutic Vaccine for the Treatment of Cancer

An active cancer vaccine strategy targeting tumor-associated carbohydrate antigens expressed on tumor cells using biomimetic glyconanoparticles generated from unique red blood cells. The resulting sustained immune response inhibits tumor growth. THE NEED While envisioned already in 1891, only a few cancer vaccines have been approved by the FDA thus far.  The key barriers to their […] Read More >

Leading Researchers:
10-2007-109

Macrolid Induced Correction of Premature Stop Codons: A novel Treatment for Colorectal Cancer

Restoration of premature termination codons (PTCs) caused by nonsense mutations for the treatment   of Familial Adenomatous Polyposis. The Need Familial Adenomatous Polyposis (FAP) is a high penetrance devastating syndrome manifested by dozens to thousands of colonic adenomas. FAP patients require tight supervision and eventually undergo surgery, to prevent inevitable development of colorectal cancer (CRC) by […] Read More >

Leading Researchers:
10-2019-1337

Anti-Cancer Nanotherapy: Targeted Potent Conjugated BRAF/MEK Inhibitors

In the last decade, deep understanding of key oncogenes and signaling pathways, involved in cancer pathogenesis and progression were achieved, leading to new treatment options. However, the number  of patients with metastatic melanoma continue to rise. This may be attributed to the prolonged life-span of cancer patients with primary tumors, enabling metastatic spread later on. […] Read More >

Leading Researchers:
10-2019-1235

Broad-Spectrum Metastasis Suppressing Compounds in Human Solid Tumors

Despite recent advances in cancer therapy, still malignancy is responsible for 15% of human death. Among these patients having solid tumors, 90% die from metastatic disease. Thus, effective prevention and suppression of metastasis is still an elusive goal.  The proposed compounds and/or their derivatives identify a potential novel therapy for a broad-spectrum of the major […] Read More >

Leading Researchers:
10-2021-1659

Novel Bcr-Abl1 Inhibitors for Treating Imatinib Resistance Cancer

The BCR-ABL1 fusion gene is the hallmark of the Philadelphia chromosome-positive (Ph+) leukemia, creating a constitutively active ABL1 tyrosine kinase. Current therapy relies on the FDA-approved tyrosine kinase inhibitors (TKIs) such as imatinib (Gleevec®), which target the ATP binding site of the BCR-ABL1 kinase. Unfortunately, the acquisition of point mutations in the ATP binding site […] Read More >

Prof. Barzel Adi

Our lab will focus on gene therapy using viral vectors. We will tackle diseases ranging from cancer to viral infections and diabetes. Devising safe and efficient gene therapies combines challenges in biochemistry and molecular biology with challenges in physiology, immunology, virology and more. We will focus on genome editing- the site specific manipulation of the […] Read More >

Prof. Ben-Eliyahu Shamgar

I am a neuroscientist specializing in Psycho-Neuro-Immunology (PNI). The field of PNI studies interactions between the central nervous system (CNS), the endocrine system, and the immune system. Bidirectional influences between these systems affect susceptibility to diseases, cognition, mood, and behavior, as well as neurodevelopmental processes. Within the realm of PNI, my main research interests are […] Read More >

Prof. Benayahu Dafna

Nanomedicine is medical treatment at the level of single molecules or molecular assemblies that provide structure, control, signaling, homeostasis, and motility in cells, i.e., at the “nano” scale of about 100 mm or less. There have been many scientific and technological advances in both physical and biological sciences over the past several years that make nano medicine […] Read More >

Prof. Benhar Itai

Prof. Benhar is an expert and opinion leader in the field of antibody engineering. Over the 25 years of being active in that field, he prepared several phage display libraries from which antibodies against numerous targets were isolated. Prof. Benhar publishes over 100research papers, wrote 10 book chapters and submitted 19 patent applications. Research in Prof. […] Read More >

Prof. Canaani Dan

Preface Previously, my laboratory has concentrated on isolation of human DNA repair genes, and in particular checkpoint genes for DNA damage. For this purpose we introduced the approach of isolating human DNA repair genes by expression cloning of cDNA libraries (Teitz et al., 1987; 1988; 1989). This approach has initially resulted in our identification of […] Read More >

Prof. Dvir Tal

Microfluidics-based tissue engineering. Recreating stem cell niches, microfluidics bioreactors for tissue engineering. Nanotechnological strategies for engineering thick cardiac tissue. Engineering a 3D neuronal network for spinal cord and brain regeneration. Fabrication of Nanoelectronics/engineered tissue hybrids. Developing smart delivery systems that recruit stem cells to defected organs. Email: tdvir@tauex.tau.ac.il Phone: 03-6406514 Another phone: 03-6408604 Website: https://dvirlab.wixsite.com/dv… Office: […] Read More >

Prof. EHRLICH Marcelo

I am interested on the dynamic aspects of the cell’s trafficking machinery, with a special focus on endocytic dynamics. More specifically, our study centers on the mechanisms by which the cell modulates vesicular traffic by altering: The rate of formation of vesicular carriers, such as clathrin coated vesicles. The spatio-temporal distribution of the process of […] Read More >

Prof. Eldar- Finkelman Hagit

My overall research is focused on elucidating the molecular and biochemical regulation of the protein kinase, glycogen synthase kinase-3 (GSK-3), and revealing its contribution to pathological disorders. GSK-3 is emerging as a prominent drug discovery target in neurodegenerative disorders including ALS, Parkinson’s, Huntington’s and Alzheimer’s disease. In a recent work we identified lysosomes as novel […] Read More >

Prof. Erez Neta

Associate Professor, Chair of the Department of Pathology, Faculty of Medicine, Tel Aviv University Research Cancer Related Inflammation in Tumor Progression and Metastasis The main goal of our laboratory is to uncover stromal pathways that contribute to tumorigenesis and metastasis. Extensive research has led to the understanding that tumors are more than just cancer cells: […] Read More >

Prof. Fishelson Zvi

Research Molecular Analysis of Cancer Immunoresistance The long-term goal of our research is to develop a novel treatment for immune resistant cancers. Our research includes characterization of the mechanism of complement-dependent cytotoxicity and of the basis for elevated resistance of cancer cells to cell death, and design of novel reagents that sensitize cancer cells to […] Read More >

Leading Researchers:
12-2016-1018

Lab of Signal transduction, Neurodegeneration and Autophagy

Research focus ErbB receptors interactions and functions Regulation of Autophagy Neurodegeneration  Projects include:The crosstalk between ErbB receprots and nucleolin in cancer developmentBeclin 1 mediated autophagyAutophagy in neurodegenerative diseasesAutophagy in cancer Potential servicesLaboratory services:To monitor autophagySignal transduction assaysAnti-cancer drugs examinationCell proliferation, death and migration examination   Potential industries1.    Pharma2.    BiotechContact InformationProf. Pinkas-Kramarski RonitDept. of Neurobiology, Life […] Read More >

Leading Researchers:
12-2016-972

Lab of Cancer Angiogenesis and Nanomedicine

Selective therapy remains a key issue for successful treatment in cancer therapy. Prolonged administration of effective concentrations of chemotherapeutic or anti-angiogenic agents is usually not possible because of dose-limiting systemic toxicities involving non-malignant tissues. Therefore, a constant effort has been the development of new drug delivery systems that mediate drug release selectively at the tumor […] Read More >

Leading Researchers:
12-2011-225

Synthesis of Organic Compounds

Custom synthesis of organic compounds   Industrial Research Services: We offer services for custom synthesis of small organic compounds. Our laboratories in Tel Aviv University have all the basic state-of-the-art instrumentation for synthetic capabilities. The School of Chemistry also has an Analytical Research and Instrumentation Unit, which provides services for organic analyses. The Department of […] Read More >

Leading Researchers:
12-2011-199

Animal Models for CNS Disorders and Screening Method for Diabetes

In vitro and in vivo animal models for stroke, Alzheimer’s disease (AD), and multiple sclerosis (MS). Rapid screening method for selecting candidates with specific insulin-degrading enzyme inhibitor activity in Types I and II  Diabetes.   https://www.tau.ac.il/lifesci/departments/neuro/members/frenkel/frenkel.html Read More >

Sorry, no results were found.

Sign up for
our events

    Close
    Life Science
    Magazine

      Close
      Hi-Tech
      Magazine

        Close